{"type":"trials","record":{"id":42074,"source_id":"clinicaltrials-gov","external_id":"NCT02581891","title":"Managing Neovascular (Known as \"Wet\") Age-related Macular Degeneration Over 2 Years Using Different Treatment Schedules of 2 mg Intravitreal Aflibercept Injected in the Eye","brief_summary":"This study aims to evaluate the optimal use, efficacy, and safety of a Treat-and-Extend regimen with aflibercept in subjects with nAMD.","overall_status":"Completed","phases":["PHASE4"],"study_type":"INTERVENTIONAL","sponsor":"Bayer","enrollment":287,"countries":["Australia","Canada","France","Germany","Hungary","Italy","Spain","United Kingdom"],"start_date":"2015-11-19","completion_date":"2019-04-26","last_update_date":"2023-11-08","source_url":"https://clinicaltrials.gov/study/NCT02581891","editorial_summary":"A registered PHASE4 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":"ARIES","age_range":"50 Years","comparator":"Late-start T&E / Arm 2","organization":"Bayer","interventions":["Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321)"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Change in BCVA as Measured by the ETDRS Letter Score — From Week 16 to Week 104","Percentage of Participants Maintaining Vision (<3 Lines Loss) at Week 104 Compared With Baseline — at Week 104","Change in BCVA From Baseline to Week 52, Baseline to Week 104, and Week 16 to Week 52 — from baseline to Week 52, basel…","Percentage of Participants Maintaining Vision (<3 Lines Loss) at Week 52 Compared With Baseline — At week 52","Percentage of Participants Gained 3-line at Week 52 and Week 104 Compared With Baseline — At Week 52 and Week 104","Change in Central Retinal Thickness (CRT) — From baseline to Week 52, baseline to Week 104, Week 16 to Week 52, and Wee…","Number of Study Drug Injections From Baseline to Week 52 and Baseline to Week 104 — At Week 52 and Week 104","Duration of Last Treatment Interval — Early-Start T&E: from week 16 up to Week 104 or early termination; Late-Start T&E…","Percentage of Participants Requiring Retreatment at 8 Weeks, 10 Weeks, 12 Weeks, 14 Weeks, and 16 Weeks as the Last Tre…"],"design_description":"RANDOMIZED · PARALLEL · TREATMENT · NONE","source_has_results":true},"controlled_terms":["Macular Degeneration","Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321)"],"relevance_confidence":80,"source_quality_score":100,"freshness_score":65,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct02581891","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2015-11-19 to 2019-04-26","comparator":"Late-start T&E / Arm 2","confidence":"structured-source","population":"ALL · 50 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.916Z","intervention":["Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321)"],"participants":287,"study_design":"RANDOMIZED · PARALLEL · TREATMENT · NONE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE4","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Change in BCVA as Measured by the ETDRS Letter Score — From Week 16 to Week 104","Percentage of Participants Maintaining Vision (<3 Lines Loss) at Week 104 Compared With Baseline — at Week 104","Change in BCVA From Baseline to Week 52, Baseline to Week 104, and Week 16 to Week 52 — from baseline to Week 52, basel…","Percentage of Participants Maintaining Vision (<3 Lines Loss) at Week 52 Compared With Baseline — At week 52","Percentage of Participants Gained 3-line at Week 52 and Week 104 Compared With Baseline — At Week 52 and Week 104","Change in Central Retinal Thickness (CRT) — From baseline to Week 52, baseline to Week 104, Week 16 to Week 52, and Wee…","Number of Study Drug Injections From Baseline to Week 52 and Baseline to Week 104 — At Week 52 and Week 104","Duration of Last Treatment Interval — Early-Start T&E: from week 16 up to Week 104 or early termination; Late-Start T&E…","Percentage of Participants Requiring Retreatment at 8 Weeks, 10 Weeks, 12 Weeks, 14 Weeks, and 16 Weeks as the Last Tre…"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Title supplies longevity context: aging, age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","title context","study type"],"relevance_score":80,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/42074","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}